EQUILLIUM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 USD | -5.52% |
|
+6.21% | +136.51% |
Presenter SpeechBruce Steel (Executives)Good morning. This is Bruce Steel, Chief Executive Off...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Companyâs pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Companyâs EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.71
USD
Average target price
6.75
USD
Spread / Average Target
+294.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +136.51% | 60.29M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Transcript : Equillium, Inc. - Analyst/Investor Day
